These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 17652190)

  • 21. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging.
    Fütterer JJ; Heijmink SW; Scheenen TW; Veltman J; Huisman HJ; Vos P; Hulsbergen-Van de Kaa CA; Witjes JA; Krabbe PF; Heerschap A; Barentsz JO
    Radiology; 2006 Nov; 241(2):449-58. PubMed ID: 16966484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases.
    Luboldt W; Küfer R; Blumstein N; Toussaint TL; Kluge A; Seemann MD; Luboldt HJ
    Radiology; 2008 Dec; 249(3):1017-25. PubMed ID: 18849502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection.
    Reinsberg SA; Payne GS; Riches SF; Ashley S; Brewster JM; Morgan VA; deSouza NM
    AJR Am J Roentgenol; 2007 Jan; 188(1):91-8. PubMed ID: 17179350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imaging prostate cancer with 11C-choline PET/CT.
    Reske SN; Blumstein NM; Neumaier B; Gottfried HW; Finsterbusch F; Kocot D; Möller P; Glatting G; Perner S
    J Nucl Med; 2006 Aug; 47(8):1249-54. PubMed ID: 16883001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines.
    Shukla-Dave A; Hricak H; Moskowitz C; Ishill N; Akin O; Kuroiwa K; Spector J; Kumar M; Reuter VE; Koutcher JA; Zakian KL
    Radiology; 2007 Nov; 245(2):499-506. PubMed ID: 17890357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate cancer: endorectal MR imaging and MR spectroscopic imaging--distinction of true-positive results from chance-detected lesions.
    Hom JJ; Coakley FV; Simko JP; Qayyum A; Lu Y; Schmitt L; Carroll PR; Kurhanewicz J
    Radiology; 2006 Jan; 238(1):192-9. PubMed ID: 16373767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility.
    Scheenen TW; Heijmink SW; Roell SA; Hulsbergen-Van de Kaa CA; Knipscheer BC; Witjes JA; Barentsz JO; Heerschap A
    Radiology; 2007 Nov; 245(2):507-16. PubMed ID: 17848681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined.
    Chen M; Dang HD; Wang JY; Zhou C; Li SY; Wang WC; Zhao WF; Yang ZH; Zhong CY; Li GZ
    Acta Radiol; 2008 Jun; 49(5):602-10. PubMed ID: 18568549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience.
    Pucar D; Shukla-Dave A; Hricak H; Moskowitz CS; Kuroiwa K; Olgac S; Ebora LE; Scardino PT; Koutcher JA; Zakian KL
    Radiology; 2005 Aug; 236(2):545-53. PubMed ID: 15972335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging.
    Kurhanewicz J; Vigneron DB; Hricak H; Parivar F; Nelson SJ; Shinohara K; Carroll PR
    Radiology; 1996 Aug; 200(2):489-96. PubMed ID: 8685346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of step-section histopathology to evaluate 18F-fluorocholine PET sextant localization of prostate cancer.
    Kwee SA; Thibault GP; Stack RS; Coel MN; Furusato B; Sesterhenn IA
    Mol Imaging; 2008; 7(1):12-20. PubMed ID: 18384719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer.
    Tuncel M; Souvatzoglou M; Herrmann K; Stollfuss J; Schuster T; Weirich G; Wester HJ; Schwaiger M; Krause BJ
    Nucl Med Biol; 2008 Aug; 35(6):689-95. PubMed ID: 18678354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings--initial observations.
    Shukla-Dave A; Hricak H; Eberhardt SC; Olgac S; Muruganandham M; Scardino PT; Reuter VE; Koutcher JA; Zakian KL
    Radiology; 2004 Jun; 231(3):717-24. PubMed ID: 15163811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MRI spectroscopy in screening of prostate cancer.
    Goeb K; Engehausen DG; Krause FS; Hollenbach HP; Niedobitek G; Buettner M; Frangou P; Engelhard K
    Anticancer Res; 2007; 27(1B):687-93. PubMed ID: 17348461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience.
    Prando A; Kurhanewicz J; Borges AP; Oliveira EM; Figueiredo E
    Radiology; 2005 Sep; 236(3):903-10. PubMed ID: 16118169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.
    Ohno Y; Koyama H; Onishi Y; Takenaka D; Nogami M; Yoshikawa T; Matsumoto S; Kotani Y; Sugimura K
    Radiology; 2008 Aug; 248(2):643-54. PubMed ID: 18539889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy.
    Yamaguchi T; Lee J; Uemura H; Sasaki T; Takahashi N; Oka T; Shizukuishi K; Endou H; Kubota Y; Inoue T
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):742-8. PubMed ID: 16052370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy.
    Zakian KL; Sircar K; Hricak H; Chen HN; Shukla-Dave A; Eberhardt S; Muruganandham M; Ebora L; Kattan MW; Reuter VE; Scardino PT; Koutcher JA
    Radiology; 2005 Mar; 234(3):804-14. PubMed ID: 15734935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology.
    Selnæs KM; Heerschap A; Jensen LR; Tessem MB; Schweder GJ; Goa PE; Viset T; Angelsen A; Gribbestad IS
    Invest Radiol; 2012 Nov; 47(11):624-33. PubMed ID: 23011187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology.
    Wefer AE; Hricak H; Vigneron DB; Coakley FV; Lu Y; Wefer J; Mueller-Lisse U; Carroll PR; Kurhanewicz J
    J Urol; 2000 Aug; 164(2):400-4. PubMed ID: 10893595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.